Research Article
BibTex RIS Cite
Year 2022, Volume: 49 Issue: 3, 414 - 421, 02.09.2022
https://doi.org/10.5798/dicletip.1170070

Abstract

References

  • 1.Bezinover D, Saner F. Organ transplantation in themodern era. BMC Anesthesiol. 2019;19(1).doi:10.1186/s12871-019-0704-z.
  • 2.Wiseman ACC. Immunosuppressive medications.Clin J Am Soc Nephrol. 2016;11(2):332-343.doi:10.2215/CJN.08570814.
  • 3.Hao Z, Sadek I. Sunitinib: The antiangiogeniceffects and beyond. Onco Targets Ther.2016;9:5495-5505. doi:10.2147/OTT.S112242.
  • 4.Mizukami A, Swiech K. Mesenchymal stromalcells: From discovery to manufacturing andcommercialization. Stem Cells Int. 2018;2018.doi:10.1155/2018/4083921.

Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic

Year 2022, Volume: 49 Issue: 3, 414 - 421, 02.09.2022
https://doi.org/10.5798/dicletip.1170070

Abstract

Objective: Mesenchymal stem cells (MSCs) are also promising in immunosuppressed patients after organ and tissue transplantation, in addition to their current wide range of uses and research areas. Sunitinib is a receptor tyrosine kinase with immunosuppressive properties and its cytotoxic activity in different types of cells is known. Our study aimed to elucidate the effect of oxytocin on sunitinib-treated MSCs.
Methods: For this purpose, commercially available rat adipose tissue-derived MSC (ADMSCs) was used. The individual or combinational effect of the active substances on viability was evaluated with WST-1, the effect on apoptosis Annexin V, the effect on oxidative stress markers MDA, CAT, GPX, and SOD ELISA tests.
Results: The IC50 value of sunitinib was determined as 44.57 μM at the 48th hour, and it was determined that oxytocin had no cytotoxic effect in doses up to 100 μM. Treatment of the two agents in combination increased the cytotoxic effect of sunitinib. Oxytocin attenuated the effect of sunitinib on apoptosis and lipid peroxidation.
Conclusion: It is important to investigate the efficacy of these two substances individually and in combination with ADMSCs with further experiments to evaluate the potential use of oxytocin in organ and tissue transplantations.

References

  • 1.Bezinover D, Saner F. Organ transplantation in themodern era. BMC Anesthesiol. 2019;19(1).doi:10.1186/s12871-019-0704-z.
  • 2.Wiseman ACC. Immunosuppressive medications.Clin J Am Soc Nephrol. 2016;11(2):332-343.doi:10.2215/CJN.08570814.
  • 3.Hao Z, Sadek I. Sunitinib: The antiangiogeniceffects and beyond. Onco Targets Ther.2016;9:5495-5505. doi:10.2147/OTT.S112242.
  • 4.Mizukami A, Swiech K. Mesenchymal stromalcells: From discovery to manufacturing andcommercialization. Stem Cells Int. 2018;2018.doi:10.1155/2018/4083921.
There are 4 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Original Articles
Authors

Meliz Sofu This is me

Bakiye Goker Bagca This is me

Derya Erısık This is me

Cigir Bıray Avcı This is me

Yigit Uyanıkgıl This is me

Publication Date September 2, 2022
Submission Date March 23, 2022
Published in Issue Year 2022 Volume: 49 Issue: 3

Cite

APA Sofu, M., Goker Bagca, B., Erısık, D., Avcı, C. B., et al. (2022). Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic. Dicle Tıp Dergisi, 49(3), 414-421. https://doi.org/10.5798/dicletip.1170070
AMA Sofu M, Goker Bagca B, Erısık D, Avcı CB, Uyanıkgıl Y. Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic. diclemedj. September 2022;49(3):414-421. doi:10.5798/dicletip.1170070
Chicago Sofu, Meliz, Bakiye Goker Bagca, Derya Erısık, Cigir Bıray Avcı, and Yigit Uyanıkgıl. “Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib Are Synergistically Dystrophic”. Dicle Tıp Dergisi 49, no. 3 (September 2022): 414-21. https://doi.org/10.5798/dicletip.1170070.
EndNote Sofu M, Goker Bagca B, Erısık D, Avcı CB, Uyanıkgıl Y (September 1, 2022) Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic. Dicle Tıp Dergisi 49 3 414–421.
IEEE M. Sofu, B. Goker Bagca, D. Erısık, C. B. Avcı, and Y. Uyanıkgıl, “Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic”, diclemedj, vol. 49, no. 3, pp. 414–421, 2022, doi: 10.5798/dicletip.1170070.
ISNAD Sofu, Meliz et al. “Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib Are Synergistically Dystrophic”. Dicle Tıp Dergisi 49/3 (September 2022), 414-421. https://doi.org/10.5798/dicletip.1170070.
JAMA Sofu M, Goker Bagca B, Erısık D, Avcı CB, Uyanıkgıl Y. Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic. diclemedj. 2022;49:414–421.
MLA Sofu, Meliz et al. “Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib Are Synergistically Dystrophic”. Dicle Tıp Dergisi, vol. 49, no. 3, 2022, pp. 414-21, doi:10.5798/dicletip.1170070.
Vancouver Sofu M, Goker Bagca B, Erısık D, Avcı CB, Uyanıkgıl Y. Adipose Tissue Mesenchymal Stem Cells Exposed To Oxytocin and Sunitinib are Synergistically Dystrophic. diclemedj. 2022;49(3):414-21.